Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery.

Syngeneic models — inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain — are invaluable preclinical research tools that enable tumour studies in the context of a complete and functional immune system. These models are powerful tools for studying  tumour-immune system interactions and investigation into new immunotherapies.

Taconic’s white paper takes a closer look at the benefits of syngeneic tumour models and provides:

  • An overview of syngeneic tumour models and their importance for immuno-oncology studies
  • A brief history of syngeneic models
  • The specific differences between syngeneic and humanised models and how this affects their suitability for particular research studies
  • The essential considerations to account for in a successful syngeneic tumour study, including genetic background, health status, and the microbiome

Authors: Caroline Horizny, PhD and Philip Dubé, PhD, Taconic Biosciences

To download the white paper click here

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free